BIOCLEAN FIRST CARE EX in Combination With Biofinity Lens
NCT ID: NCT02196766
Last Updated: 2020-07-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2014-07-31
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BIOCLEAN MPS (Multi-Purpose Solution) VII in Combination With Biofinity Lens: A Two Week Crossover Study
NCT02537730
The Clinical Performance of the Biofinity Contact Lens (Comfilcon A) With Two Lens Care Systems
NCT02510820
Clinical Validation of Biofinity Toric MTO (Made To Order) Lenses
NCT02185105
Evaluation of Comfilcon A and Senofilcon A Lenses
NCT01695369
Clinical Evaluation of Proclear Toric and Biofinity Toric
NCT06431061
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bioclean First Care EX combo, then Aosept Clearcare combo
Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the Aosept Clearcare / comfilcon A combination.
Bioclean First Care EX / comfilcon A
Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.
Aosept Clearcare / comfilcon A
Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.
Aosept Clearcare combo, then Bioclean First Care EX combo
Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the Bioclean First Care EX / comfilcon A combination.
Bioclean First Care EX / comfilcon A
Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.
Aosept Clearcare / comfilcon A
Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bioclean First Care EX / comfilcon A
Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.
Aosept Clearcare / comfilcon A
Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has had a self-reported visual exam in the last two years
* Is currently an adapted spherical soft CL wearer
* Has a CL spherical prescription between - 0.25 and - 12.00 (inclusive)
* Has less than 1.00D spectacle cylinder in each eye.
* Is correctable to a visual acuity of 20/20 or better in both eyes
* Has clear corneas and no active ocular disease
* Has read, understood and signed the information consent letter.
* Is willing to comply with the wear schedule (at least 40 hrs per week)
* Is willing to comply with the visit schedule
Exclusion Criteria
* Currently wears rigid gas permeable contact lenses.
* Has a history of not achieving comfortable CL wear (5 days per week; \> 8 hours/day)
* Has a CL prescription outside the range of - 0.25 to -12.00D
* Has a spectacle cylinder greater than -0.75D of cylinder in either eye.
* Has best corrected spectacle distance vision worse than 20/20 in either eye.
* Has any systemic disease affecting ocular health.
* Is using any systemic or topical medications that will affect ocular health.
* Has any ocular pathology or severe insufficiency of lacrimal secretion
* Has persistent, clinically significant corneal or conjunctival staining
* Has active neovascularization or any central corneal scars.
* Is aphakic.
* Is pregnant or lactating.
* Has undergone corneal refractive surgery.
* Is participating in any other type of eye related clinical or research study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CooperVision, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Taku Muraoka, OD
Role: STUDY_DIRECTOR
Director Professional Services, CVI Japan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kokama Eye Clinic
Joyo-shi, Kyoto, Japan
Higashihara Clinic
Kameoka, Kyoto, Japan
Dougenzaka Ioti Eye Clinic
Shibuya-ku, Tokyo-to, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CVJ-EX-MKTG-1818
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.